← Back to Search

LVAD Implant

The ARIES HeartMate 3 Pump IDE Study

N/A
Waitlist Available
Research Sponsored by Abbott Medical Devices
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years post implant

Summary

This trial looked at whether adding aspirin to a vitamin K antagonist improved outcomes in heart failure patients.

Eligible Conditions
  • Heart Failure
  • Congestive Heart Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years post implant
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years post implant for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Non-Inferiority Primary Endpoint
Secondary study objectives
Rate of Bleeding Rates
Hemorrhage
Rate of Non-surgical Major Thrombotic Events
+3 more
Other study objectives
Economic Cost Implications
Rate of Rehospitalization
The Hemocompatibility Score (HCS)

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active ArmActive Control2 Interventions
LVAD Patients on the active arm will be given 100mg Aspirin
Group II: Placebo ArmPlacebo Group2 Interventions
LVAD Patients on the placebo arm will be given placebo medication

Find a Location

Who is running the clinical trial?

Abbott Medical DevicesLead Sponsor
652 Previous Clinical Trials
416,209 Total Patients Enrolled
126 Trials studying Heart Failure
52,123 Patients Enrolled for Heart Failure
Poornima Sood, MD, MBAStudy DirectorClinical Program Director
7 Previous Clinical Trials
4,109 Total Patients Enrolled
6 Trials studying Heart Failure
4,100 Patients Enrolled for Heart Failure
~116 spots leftby Jan 2026